DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

Sortera Bio, a Cambridge biotech based on IP developed at the MRC Laboratory of Molecular Biology, has attracted big hitting ...

AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the ...

Danaher Corp on Thursday said it has entered a partnership with AstraZeneca PLC to develop and commercialise tools and tests for precision medicine treatments, including artificial intelligence ...

The Cambridge Independent Business Awards 2025 are now open for entry. Following the success of our inaugural awards last year, we are delighted to announce that the search is now on for the best in ...

A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...

effective today. The announcement was made in compliance with Listing Rule 6.4.9 (2). Headquartered in Cambridge, UK, AstraZeneca (NASDAQ:AZN) is focused on the discovery, development, and ...

AstraZeneca and the UK's Medical Research Council have unveiled a groundbreaking collaboration which will see them working hand-in-hand in a joint research facility in Cambridge in the UK.

Multinationals on China: China has set a GDP growth target of around 5% for 2025. How do you view this target and China’s ...

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) ...

Treating patients with a drug before surgery greatly reduced the chances of the cancer coming back, a small trial found.

After years of delays and rising costs, AstraZeneca has formally unveiled its $1 billion R&D facility in Cambridge, said to be the biggest science lab of its kind in the UK.